London, UK 21 August 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease, today announced that results from its two pivotal Phase III trials of GMRx2 have been selected for oral presentation during a Hot Line Session of the European Society of Cardiology (ESC) Congress, taking place from 30 August to 2 September 2024 in London, UK, and online.
Dr Anthony Rodgers, Chief Medical Officer of George Medicines and Professorial Fellow at The George Institute for Global Health, will present results from two international Phase III trials investigating GMRx2, George Medicines’ novel, multi-mechanism triple combination candidate for the treatment of hypertension, including initiation of treatment. GMRx2 contains best-in-class medicines, telmisartan, amlodipine and indapamide, in triple quarter-dose (ultra-low dose), triple half dose (low dose) and triple standard dose options.
| Session: | Hot Line 2 |
| Oral Presentation: | GMRx2 – Efficacy and safety of a novel triple single pill combination |
| Presenting Author: | Dr Anthony Rodgers |
| Date and Time: | Saturday 31 August, 08:15 – 09:46 BST |
Mark Mallon, Chief Executive Officer of George Medicines, said: “GMRx2 has the potential to transform the management of hypertension, with a multi-mechanism, low dose approach that delivers the synergistic efficacy benefits of a triple therapy, while maintaining tolerability and in a single pill that can be expected to improve patient adherence. We look forward to sharing the latest evidence supporting this drug candidate with scientific colleagues in London and around the world.”
The Hot Line session will also include an oral presentation by Dr Dike Bevis Ojji, University of Abuja, Nigeria, reporting results from the VERONICA (deliVERy of Optimal blood pressure coNtrol in afrICA) clinical trial, conducted in hospital-based family medicine clinics in Nigeria. The trial was supported by The George Institute for Global Health and the National Health and Medical Research Council (NHMRC) of Australia, with medicine supplied by George Medicines.
Ends
About the European Society of Cardiology Congress 2024
The ESC Congress is the world’s largest conference in cardiovascular medicine, bringing together leading cardiology experts from more than 150 countries to share groundbreaking science and essential clinical updates, with the shared goal of advancing cardiovascular medicine worldwide.
About George Medicines
George Medicines is a late-stage biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic diseases with innovative combinations of best-in-class existing treatments, designed for optimal efficacy and safety.
Combining best-in-class molecules from existing medicines in novel low-dose formulations, George Medicines is developing innovative and proprietary treatments to be more efficacious, safer and accessible than currently available treatment options. These multi-mechanism, single-pill combinations offer the potential to bring significant improvements in clinical outcomes and therapy adherence in patients with cardiometabolic disorders, including hypertension and diabetes, each of which remain the leading causes of premature death and disability worldwide.
The Company’s lead candidate, GMRx2, has completed a Phase III development program for the treatment of hypertension, including first-line therapy, and a global trial focused on the prevention of recurrent intracerebral hemorrhage (the most severe type of stroke) is underway.
George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes with a focus on addressing global health inequity. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm. For more information, please visit www.george-medicines.com.
Media contacts
ICR Consilium
David Daley, Lindsey Neville, Isabelle Abdou
georgemedicines@consilium-comms.com
Tel: +44 (0) 203 709 5700